相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients
Priya Bhusari et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Preparation and preclinical evaluation of 131I-trastuzumab for breast cancer
Mythili Kameswaran et al.
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS (2017)
Development and preclinical studies of 64Cu-NOTA-pertuzumab F(ab′)2 for imaging changes in tumor HER2 expression associated with response to trastuzumab by PET/CT
Karen Lam et al.
MABS (2017)
Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with 177Lu
Zhongli Cai et al.
PHARMACEUTICAL RESEARCH (2017)
New small 99mTc-labeled peptides for HER2 receptor imaging
Hamideh Sabahnoo et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT
Dan Sandberg et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer
Dawei Jiang et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?
Angela Toss et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe 99mTc-HYNIC-H6F in Breast Cancer Mouse Models
Liqiang Li et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
64Cu-Labeled Trastuzumab Fab-PEG24-EGF Radioimmunoconjugates Bispecific for HER2 and EGFR: Pharmacokinetics, Biodistribution, and Tumor Imaging by PET in Comparison to Monospecific Agents
Luke Yongkyu Kwon et al.
MOLECULAR PHARMACEUTICS (2017)
Cancer Statistics, 2017
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial
G. Gebhart et al.
ANNALS OF ONCOLOGY (2016)
Phase I Study of Ga-68-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma
Marleen Keyaerts et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates
Eva J. Razumienko et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
HER-2 Positive Breast Cancer - a Mini-Review
Hafiz Muhammad Asif et al.
Asian Pacific Journal of Cancer Prevention (2016)
Zevalin® (ibritumomab tiuxetan): After more than a decade of treatment experience, what have we learned?
David Rizzieri
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment
Guowei Gu et al.
CURRENT OPINION IN PHARMACOLOGY (2016)
ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy
Patricia V. Elizalde et al.
ENDOCRINE-RELATED CANCER (2016)
Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment
Keith T. Schmidt et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Nuclear Medicine in Cancer Theranostics: Beyond the Target
David Taieb et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Imaging Diagnostic and Therapeutic Targets: Human Epidermal Growth Factor Receptor 2
Geraldine Gebhart et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT
Gary A. Ulaner et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients
Mattias Sandstrom et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
[89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer
Richard Laforest et al.
MOLECULAR IMAGING AND BIOLOGY (2016)
A comparative evaluation of the chelators H4octapa and CHX-A-DTPA with the therapeutic radiometal 90Y
Eric W. Price et al.
NUCLEAR MEDICINE AND BIOLOGY (2016)
111In-labeled trastuzumab-modified gold nanoparticles are cytotoxic in vitro to HER2-positive breast cancer cells and arrest tumor growth in vivo in athymic mice after intratumoral injection
Zhongli Cai et al.
NUCLEAR MEDICINE AND BIOLOGY (2016)
Evaluation of a 3-hydroxypyridin-2-one (2,3-HOPO) Based Macrocyclic Chelator for 89Zr4+ and Its Use for ImmunoPET Imaging of HER2 Positive Model of Ovarian Carcinoma in Mice
Jeff N. Tinianow et al.
THERANOSTICS (2016)
Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT
Jens Sorensen et al.
THERANOSTICS (2016)
Macrocycle-Based Hydroxamate Ligands for Complexation and Immunoconjugation of 89Zirconium for Positron Emission Tomography (PET) Imaging
Eszter Boros et al.
CHEMPLUSCHEM (2016)
Dual-Labeled Near-Infrared/99mTc Imaging Probes Using PAMAM-Coated Silica Nanoparticles for the Imaging of HER2-Expressing Cancer Cells
Haruka Yamaguchi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants
Fresia Pareja et al.
NPJ BREAST CANCER (2016)
Mechanisms of Cell Killing Response from Low Linear Energy Transfer (LET) Radiation Originating from 177Lu Radioimmunotherapy Targeting Disseminated Intraperitoneal Tumor Xenografts
Kwon Joong Yong et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Twenty years of anti-HER2 therapy-associated cardiotoxicity
Noam F. Ponde et al.
ESMO OPEN (2016)
Kit for the preparation of 111In-labeled pertuzumab injection for imaging response of HER2-positive breast cancer to trastuzumab (Herceptin)
Karen Lam et al.
APPLIED RADIATION AND ISOTOPES (2015)
Transcriptomic Signatures of Auger Electron Radioimmunotherapy Using Nuclear Targeting 111In-Trastuzumab for Potential Combination Therapies
Huizi Keiko Li et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2015)
Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of 111In-BzDTPA-pertuzumab
Karen Lam et al.
NUCLEAR MEDICINE AND BIOLOGY (2015)
188Re-HYNIC-trastuzumab enhances the effect of apoptosis induced by trastuzumab in HER2-overexpressing breast cancer cells
Tsai-Yueh Luo et al.
ANNALS OF NUCLEAR MEDICINE (2015)
188Re-ZHER2:V2, a Promising Affibody-Based Targeting Agent Against HER2-Expressing Tumors: Preclinical Assessment
Mohamed Altai et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule
Jens Sorensen et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Evaluation of 89Zr-pertuzumab in Breast Cancer Xenografts
Bernadette V. Marquez et al.
MOLECULAR PHARMACEUTICS (2014)
Nanobody: The Magic Bullet for Molecular Imaging?
Rubel Chakravarty et al.
THERANOSTICS (2014)
Core Needle Biopsy of Breast Cancer Tumors Increases Distant Metastases in a Mouse Model
Edward Gitau Mathenge et al.
NEOPLASIA (2014)
Designing the Magic Bullet? The Advancement of Immuno-PET into Clinical Use
Brian D. Wright et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
Ron Bose et al.
CANCER DISCOVERY (2013)
Routine Production of 89Zr Using an Automated Module
A. Lake Wooten et al.
APPLIED SCIENCES-BASEL (2013)
What is the role of the Bystander response in radionuclide therapies?
Darren Brady et al.
FRONTIERS IN ONCOLOGY (2013)
Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas
A. Gallardo et al.
BRITISH JOURNAL OF CANCER (2012)
Role of Antibody-Mediated Tumor Targeting and Route of Administration in Nanoparticle Tumor Accumulation in Vivo
Niladri Chattopadhyay et al.
MOLECULAR PHARMACEUTICS (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts
Nasir Abbas et al.
NUCLEAR MEDICINE COMMUNICATIONS (2012)
Theranostics: Combining Imaging and Therapy
Sneha S. Kelkar et al.
BIOCONJUGATE CHEMISTRY (2011)
In vivo biodistribution and accumulation of 89Zr in mice
Diane S. Abou et al.
NUCLEAR MEDICINE AND BIOLOGY (2011)
Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer
E. C. Dijkers et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine
Maria J. W. D. Vosjan et al.
NATURE PROTOCOLS (2010)
177Lu labeling of Herceptin and preclinical validation as a new radiopharmaceutical for radioimmunotherapy of breast cancer
Samira Rasaneh et al.
NUCLEAR MEDICINE AND BIOLOGY (2010)
Preparation and evaluation of 186/188Re-labeled antibody (A7) for radioimmunotherapy with rhenium(I) tricarbonyl core as a chelate site
Kazuma Ogawa et al.
ANNALS OF NUCLEAR MEDICINE (2009)
Clinical Practice Patterns and Cost Effectiveness of Human Epidermal Growth Receptor 2 Testing Strategies in Breast Cancer Patients
Kathryn A. Phillips et al.
CANCER (2009)
Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
Werner Scheuer et al.
CANCER RESEARCH (2009)
Radiolabeling of trastuzumab with 177Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancer
Samira Rasaneh et al.
NUCLEAR MEDICINE AND BIOLOGY (2009)
The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis
M. M. Moasser
ONCOGENE (2007)
[Lu-177]pertuzumab: Experimental therapy of HER-2-expressing xenografts
Mikael Persson et al.
CANCER RESEARCH (2007)
[177Lu]pertuzumab:: experimental studies on targeting of HER-2 positive tumour cells
M Persson et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2005)
Production logistics of 177Lu for radionuclide therapy
MRA Pillai et al.
APPLIED RADIATION AND ISOTOPES (2003)
The ErbB signaling network: receptor heterodimerization in development and cancer
MA Olayioye et al.
EMBO JOURNAL (2000)
分享论文
